M&A Deal Summary

Co-Diagnostics Acquires Idaho Molecular

On December 22, 2021, Co-Diagnostics acquired life science company Idaho Molecular

Acquisition Highlights
  • This is Co-Diagnostics’ 1st transaction in the Life Science sector.
  • This is Co-Diagnostics’ 1st transaction in the United States.
  • This is Co-Diagnostics’ 1st transaction in Utah.

M&A Deal Summary
Date 2021-12-22
Target Idaho Molecular
Sector Life Science
Buyer(s) Co-Diagnostics
Deal Type Add-on Acquisition

Target

Idaho Molecular

Salt Lake City, Utah, United States
Idaho Molecular is a provider of novel solutions to human health using biotechnology. Idaho Molecular is based in Salt Lake City, Utah.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Co-Diagnostics

Salt Lake City, Utah, United States
Category Company
Founded 2013
Sector Life Science
Employees155
Revenue 7M USD (2023)
DESCRIPTION

Co-Diagnostics is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers. Co-Diagnostics was founded in 2013 and is based in Salt Lake City, Utah.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Utah) 1 of 1
Country (United States) 1 of 1
Year (2021) 1 of 1
Mergr

Product

Company

Legal